Benefits From Bimodal Fittings With Cochlear Implant and Hearing Aid vs Bilateral Hearing Aids
Hearing Loss, Cochlear
About this trial
This is an interventional treatment trial for Hearing Loss, Cochlear
Eligibility Criteria
Inclusion Criteria:
- Adults >18 years old.
- Fluent in Danish, including reading and writing
- Willing to participate in and to comply with all requirements of the protocol.
- Post-lingual deafness and use one or two HAs.
- Participants should have aidable hearing in the ear not considered for CI implantation
- Self-reported HA use of at least eight hour per day for at least one year in both ears prior to evaluation for cochlear implantation in order to ensure, that both ears have received auditive stimulation prior to participation in the study. If possible, the validity of the self-reported hearing aid use will be checked in the HA-log by the audiology assistants.
- Participants should have a PTA (0.5,1,2,4 kHz) > 40 dB HL in the ear considered for CI implantation and PTA≥40 and ≤ 70dB HL in the ear not considered for implantation.
- A speech identification score <50 % in the poorer hearing ear, i.e., the ear considered for implantation, and <70% in the best-aided condition is required.
Exclusion Criteria:
- Unwilling or unable to comply with investigational requirements.
- Normal hearing in the better hearing ear (single-sided deafness).
- Not using HAs; long-term, un-stimulated deafness defined as no acoustic stimulation (aided or normal) in one or both ears greater than one year, which will be judged based on patient interviews and through hearing aid log data.
- Vestibular loss in the ear not considered for CI implantation, which will be determined by the video Head Impulse Test (vHIT) prior to implantation.
- Surgical issues interfering with the site of implantation or anatomical contraindications such as cochlear malformations.
- Medical contraindications such as chronic middle ear disease.
- Tympanic membrane perforations.
- Auditory nerve lesions.
- Central auditory pathway pathologies.
- Otosclerosis.
Sites / Locations
- Ear nose and throat department/Hearing-clinic Odense University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Bimodal solution with cochlear implant and hearing aid (CI+HA)
Bilateral new replacement Hearing Aids (HA+HA)
This Arm will serve as the intervention group. Patients referred for evaluation of cochlear implant candidacy at Odense University Hospital will be screened for eligibility in this study and invited to participate. All patients receive new replacement HAs that can later be fitted with the CI in a bimodal solution. The patients will use the new replacement HAs for one month and are then randomized to either the intervention group with CI+HA or to the control group with continuous use of HA+HA (bilateral) for another two months. Patients randomized to the intervention group CI+HA will undergo surgery as soon as possible after randomization. Patients with the bimodal solution CI+HA will undergo follow-up one, three, six and twelve months after CI fitting.
This Arm will serve as the control group. The patients in the control group will use the new replacement HAs for one month like the intervention group and then for another three months, if they complete the study. The control group using the new replacement HAs for three months after randomization, will be offered the bimodal solution with CI to the poorer hearing ear and have the same follow-up period as the intervention group after a total of four months with new replacement HAs.